CardioNet's� (NASDAQ: BEAT ) results for the fiscal Q1 2013 have been released. For the quarter, top line came in at $32.4 million, a nearly 20% increase from the $27.0 million recorded in the same period the previous year. Net loss narrowed over that time span, to $2.1 million ($0.08 per diluted share) from Q1 2012's red figure of $3.5 million ($0.14).
CardioNet attributed the higher revenue figure to growth in its take for research services, which improved by $5.4 million on a year-over-year basis. This was due in large part to its acquisition of research entity Cardiocore last summer. Additionally, patient services revenue was $1.0 million higher in the most recent quarter.
Top 10 Biotech Companies To Invest In Right Now: Eastman Chemical Company (EMN)
Eastman Chemical Company, a chemical company, engages in the manufacture and sale of chemicals, plastics, and fibers in the United States and internationally. The company operates in four segments: Coatings, Adhesives, Specialty Polymers, and Inks (CASPI); Fibers; Performance Chemicals and Intermediates (PCI); and Specialty Plastics. The CASPI segment manufactures resins, specialty polymers, and solvents that are used in the production of paints and coatings, inks, adhesives, and other formulated products. The Fibers segment offers Estron acetate tow and Estrobond triacetin plasticizers used in cigarette filters; Estron natural and Chromspun solution-dyed acetate yarns for use in apparel, home furnishings, and industrial fabrics; and cellulose acetate flake and acetyl raw materials for acetate fiber producers. The PCI segment offers intermediates; performance chemicals; and complex organic molecules, such as diketene derivatives, specialty ketones, and specialty anhydrides for medical, pharmaceutical, fiber, and food and beverage ingredients, which are used in specialty market applications. This segment?s products are used in various markets and end uses, including agriculture, transportation, beverages, nutrition, pharmaceuticals, coatings, medical devices, toys, adhesives, household products, polymers, textiles, and consumer and industrial products, as well as used for health and wellness uses. The Specialty Plastics segment primarily offers engineering and specialty polymers, specialty film and sheet products, and packaging film and fiber products. This segment?s products include specialty copolyesters and cellulosic plastics, which are used in specialty packaging, in-store fixtures and displays, consumer and durable goods, medical goods, personal care and consumer packaging, photographic film, optical film, fibers/nonwovens, tapes/labels, and LCD?s. The company was founded in 1920 and is headquartered in Kingsport, Tennessee.
Advisors' Opinion:- [By John Divine]
Quarterly results, or a lack thereof, were also the Achilles' heel of Eastman Chemical (NYSE: EMN ) , which shed 5.1% today. Earnings actually came in above expectations, but sales numbers just didn't cut it, even though the company reported higher revenue in every single geographic region it reports in. Asia especially stood out as a segment of rapid growth, with those sales rocketing more than 50% higher. Although 48% sales growth in Europe, the Middle East, and Africa isn't too shabby, either, especially considering the macroeconomic worries and political instability surrounding those parts of the world.
- [By Seth Jayson]
Eastman Chemical (NYSE: EMN ) is expected to report Q2 earnings on July 29. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Eastman Chemical's revenues will increase 29.2% and EPS will expand 17.1%. - [By Lauren Pollock]
Eastman Chemical Co.'s(EMN) third-quarter earnings surged as the diversified chemical and materials producer reported sales growth as well as fewer charges related to its acquisition of Solutia Inc. last year. But it lowered its earnings estimate for the year on expectations it will continue to face challenges in its adhesives and plasticizers business, as well as higher raw-materials and energy costs. Shares dropped.
Hot Sliver Companies For 2014: Societe Libanaise des Ciments Blancs SAL (CBN)
Societe Libanaise des Ciments Blancs SAL is a Lebanon-based joint stock company that operates in the construction materials industry sector. The Company is engaged in the production and sale of white cement. The Company is a 65.99% owned by Holcim (Liban) SAL. Advisors' Opinion:- [By CanadianValue]
Nigeria�� reformed banking system has provided many foreigners with an attractive means to invest in the fast-growing domestic economy. The banking industry is important, not only because of the rise of microfinance, but because of the move by banks into consumer banking. Until recently, banks were mainly financing large businesses or the government through bond purchases. Following a banking crisis in 2008, the Central Bank of Nigeria (CBN) conducted an audit of the commercial banking sector. All banks that failed the audit had their CEOs replaced. The state-owned Asset Management Corporation (AMCON) was created to purchase non-performing loans and recapitalize the unhealthy banks. A recent review of the country�� banks by the IMF showed a dramatic increase in profits for the industry in 2012, while the capital adequacy ratio was above the minimum requirement of 10% and non-performing loans were below the mandated threshold of 5%5.
Hot Sliver Companies For 2014: Virgin Media Inc.(VMED)
Virgin Media Inc., through its subsidiaries, provides entertainment and communications services in the United Kingdom. The company offers cable broadband Internet, television, and fixed line telephone services under the Virgin Media brand to residential customers; mobile telephony services through Virgin Mobile, a mobile virtual network operator; broadband and telephone services to residential customers through third-party telecommunications networks; and video on demand services, including access to movies, television programs, music videos, and other on-demand content, as well as provides digital video recorders. It also offers voice, data, and Internet solutions to commercial customers comprising analog telephony and managed data networks and applications, as well as supplies communications services to health and emergency services providers. As of December 31, 2011, the company provided cable broadband services to approximately 4 million subscribers; cable television s ervices to approximately 3.76 million residential subscribers; cable telephony services to approximately 4.2 million residential subscribers; mobile telephony services to approximately 3 million customers; non-cable fixed line telephone services to approximately 163,300 subscribers; and voice, data, and Internet solutions to approximately 50,000 businesses and 250 public sector organizations. The company offers its products and services through telesales, customer care centers, and online, as well as through its sales force. It serves mobile and fixed-line service providers, systems integrators, and Internet service providers; and private and public sector organizations. The company was formerly known as NTL Incorporated and changed its name to Virgin Media Inc. in February 2007. The company was founded in 1993 and is based in New York, New York.
Advisors' Opinion:- [By Markos Kaminis]
Whether the stock is overvalued or not does not matter at this point, because an impact to its subscriber base due to the data sharing news would probably change market expectations for the company's operations and affect both earnings estimates and valuation multiples. It would probably drive the shares lower in my view, and I see no reason to risk that by holding the stock. Long-term holders, of course, have tax considerations to consider, and the news is still filing out. If Verizon's peers are also implicated clearly, perhaps with the aid of a Verizon PR push, this issue would be effectively mitigated. Though even in that case, there could be market share loss by all major American firms, with companies like T-Mobile US (TMUS) and Virgin Media (VMED) benefiting, whether they have also been involved or not. In any event, for new stakeholders, or those willing to deal with tax implications; or for those interested in a potential short opportunity, I would sell the stock today. I see no reason to bear risk while this issue and its implications are still unraveling, and while VZ has thus far not been significantly discounted for it.
Hot Sliver Companies For 2014: Medical Properties Trust Inc (MPW)
Medical Properties Trust, Inc., incorporated on August 27, 2003, is a self-advised real estate investment trust (REIT) focused on investing in and owning net-leased healthcare facilities. The Company conducts substantially all of its business through MPT Operating Partnership, L.P. The Company acquires and develops healthcare facilities and leases the facilities to healthcare operating companies under long-term net leases, which require the tenant to bear the costs associated with the property. The Company also makes mortgage loans to healthcare operators collateralized by their real estate assets. In addition, the Company selectively makes loans to certain of its operators through its taxable REIT subsidiaries. In September 2013, Medical Properties Trust Inc completed the acquisition of the real estate of three acute care hospitals operated by IASIS Healthcare LLC.
As of February 18, 2013, the Company's portfolio consists of 82 properties: 69 facilities (of the 74 facilities that the Company owns) are leased to 23 tenants, five are under development, and the remainder are in the form of mortgage loans to three operators. The Company's owned facilities consist of 27 general acute care hospitals, 24 long-term acute care hospitals, 15 inpatient rehabilitation hospitals, two medical office buildings, and six wellness centers. The non-owned facilities on which the Company has made mortgage loans consist of three general acute care facilities, two long-term acute care hospitals, and three inpatient rehabilitation hospitals. At December 31, 2012, no one property accounted for more than 5% of the Company's total assets.
At December 31, 2012, the Company had leases with 22 hospital operating companies, eight mortgaged loans, six under development, and one property under re-development covering 82 facilities. Ernest leased 12 of these facilities pursuant to a master lease agreement. The master lease agreement has a 20-year term with three five-year extension options and provides for ! an initial rental rate of 9%, with consumer price-indexed increases, limited to a 2% floor and 5% ceiling annually thereafter. At December 31, 2012, these facilities had an average remaining lease term of approximately 19 years. In addition to the master lease, the Company holds a mortgage loan on four facilities owned by affiliates of Ernest.
Affiliates of Prime Healthcare Services, Inc. (Prime) leased 11 facilities pursuant to master lease agreements. The master leases are for 10 years commencing July 3, 2012 and contain two renewal options of five years each. The initial lease rate is generally consistent with the blended average rate of the prior lease agreements. However, the annual escalators, which in the prior leases were limited, have been increased to reflect 100% of CPI increases, along with a 2% minimum floor. The master leases include repurchase options substantially similar to those in the prior leases, including provisions establishing minimum repurchase prices equal to the Company's total investment. In addition to leases, the Company holds mortgage loans on three facilities owned by affiliates of Prime.
Advisors' Opinion:- [By Brad Thomas]
A Bank of America (BOA) downgrade sends Medical Properties Trust (MPW) tumbling. The bank cut the shares to Underperform from Neutral citing the REIT's YTD outperformance relative to the sector overall (it has outpaced healthcare REITs two to one). Put simply, funds from operations "multiple expansion has exceeded fundamental trends." SA contributor Brad Thomas claims MPW is an example of mispriced risk.
- [By Eric Volkman]
It was an impressive quarter for Medical Properties Trust (NYSE: MPW ) . In its Q1 report, revenues amounted to $58 million, up 42% from the $41 million in the same period the previous year. Attributable net profit advanced much more strongly, growing 148% to $26 million ($0.18 per diluted share) from Q1 2012's figure of $11 million ($0.08). Funds from operations -- a key metric for real estate investment trusts -- came in at $35 million ($0.25 per diluted share) on a normalized basis, compared with $22 million ($0.18) in the year-ago quarter.
- [By Rich Duprey]
Real estate investment trust�Medical Properties Trust� (NYSE: MPW ) �announced yesterday�its second-quarter dividend of $0.20 per share, the same rate it's paid since 2008.
Hot Sliver Companies For 2014: Hologic Inc.(HOLX)
Hologic Inc. develops, manufactures, and supplies diagnostic, medical imaging systems, and surgical products for the healthcare needs of women. The company operates in four segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment offers breast imaging products, such as Selenia full field digital mammography system, breast tomosynthesis, healthcome mammography products, screen-film mammography systems, SecurView workstation, CAD systems, stereotactic breast biopsy systems, breast biopsy products, breast brachytherapy products, MammoPad breast cushions, and photoconductor coatings, as well as Sentinelle medical MRI breast coils and workstations. This segment also develops a breast imaging platform, Dimensions, which utilizes a tomosynthesis technology to produce 3D images. The Diagnostics segment provides ThinPrep system, a solution for cervical cancer screening; rapid fetal fibronectin test for pre-term birth risk assessment; and hu man papillomavirus offering and InVitro diagnostics for cervical cancer tests. The GYN Surgical segment offers NovaSure system, a minimally-invasive procedure that allows physicians to treat women suffering from excessive menstrual bleeding; MyoSure system for the hysteroscopic removal of fibroids; and Adiana system, a form of permanent female contraception intended as an alternative to tubal ligation. The Skeletal Health segment provides QDR X-Ray bone densitometers that assess the bone density of fracture sites; Sahara clinical bone sonometers, which assess the bone density of heels; and Mini C-Arm imaging systems that are used to perform minimally invasive surgical procedures on a patient?s extremities. Hologic Inc. sells its products through a combination of direct sales and service forces, a network of independent distributors, and sales representatives primarily in the United States, Europe, and the Asia-Pacific. The company was founded in 1985 and is headquartered in Bedford, Massachusetts.
Advisors' Opinion:- [By Ben Levisohn]
Shares of Hologic (HOLX) have plunged today after the maker of medical devices for women reported results that left investors searching for a diagnosis.
The Associated Press has the details:
Hologic said late Monday that it expects lower sales of ThinPrep pap tests, NovaSure endometrial ablations systems, and blood screening tests. Hologic also said sales of its older 2-dimensional Selenia digital mammography system will decline as it begins selling its newer Dimensions systems. The company expects to report adjusted net income of $1.32 to $1.38 per share in its new fiscal year, which started Sept. 29. It forecast $2.43 billion to $2.48 billion in total revenue, down from $2.49 billion in fiscal 2013.
Analysts had predicted much higher net income of $1.63 per share and $2.59 billion in revenue, according to FactSet.
Citigroup’s Amit Bhalla summarizes the good and the bad:
While HOLX beat the Street by $0.02 on the bottom-line, revenues came in light and F2014 guidance was below Street expectations. 3D mammo remains a positive (+50% Y/Y) and GPRO was up +11%, but ThinPrep (-13% Y/Y) and NovaSure weakness remain a headwind. Initial F14 guidance includes revs down -1-3% (Street expected +3%) and during this “transition” year, HOLX expects to complete more asset reviews/sales, further streamline the business, and begin a new $250M share buyback. While we believe these efforts are a positive, a $1.1B write-down on diagnostics (GPRO & ThirdWave) indicates that some businesses may need more time to recover ��we remain Neutral-rated.
Canaccord Genuity’s Jason Mills and team are not pleased. They write:
HOLX�� commentary at fall brokerage meetings portended a flattish outlook for FY14, but actual ��4 guidance on the Q4 call painted an even worse picture of current fundamentals, in our view. While we recognize management is likely attempting to mitigate quarterly misses and suggested FY15 sh
- [By John Udovich]
On Monday, small cap molecular diagnostic stock Myriad Genetics, Inc (NASDAQ: MYGN) suddenly sank 9.34% to $23.50 just before the market closed���meaning its probably a good idea to take a closer look at what happened yesterday plus compare the stock�� performance verses small cap peer Sequenom, Inc (NASDAQ: SQNM) and mid cap peer Hologic, Inc (NASDAQ: HOLX).�
- [By John Udovich]
Yesterday, mid cap women�� health stock Hologic, Inc (NASDAQ: HOLX) fell more than 10% after disappointing Wall Street on earnings,�meaning it might be time to take a look at it and�small cap women�� health stocks�The Female Health Company (NASDAQ: FHCO) and TherapeuticsMD Inc (NYSEMKT: TXMD) because after all, women account for half the population and these three small caps are all focused on the women�� health:
Hot Sliver Companies For 2014: Fonar Corporation(FONR)
FONAR Corporation engages in the research, development, production, marketing, and service of magnetic resonance imaging (MRI) scanners for the detection and diagnosis of human diseases. It provides Upright Multi-positional MRI scanners, which allow patients to be scanned in a weight-bearing condition, such as standing, sitting, or bending in any position that causes symptoms; and FONAR 360 MRI scanner, a diagnostic scanner. The company, through its wholly owned subsidiary, Health Management Corporation of America, also offers management services to imaging facilities, including development, administration, and leasing of office space, facilities, and medical equipment; provision of supplies; staffing, training, and supervision of non-medical personnel; legal services; accounting, billing, and collection; and the development and implementation of practice growth and marketing strategies. It serves private diagnostic imaging centers and hospitals. As of June 30, 2011, the c ompany managed 10 diagnostic imaging facilities located in the states of New York and Florida. FONAR Corporation was founded in 1978 and is based in Melville, New York.
Advisors' Opinion:- [By Monica Gerson]
Breaking news
NASDAQ OMX Group (Nasdaq: NDAQ) and Borsa Istanbul A.S. have today concluded a wide-ranging agreement, which includes the delivery of market-leading technologies and advisory services to Borsa Istanbul, and NASDAQ OMX taking an equity stake in Borsa Istanbul. To read the full news, click here. Acacia Research (NASDAQ: ACTG) announced today that its Bolt MRI Technologies LLC subsidiary has entered into an agreement with Fonar Corporation (NASDAQ: FONR). To read the full news, click here. Douglas Emmett, (NYSE: DEI) announced that William Kamer will be retiring from full time service as its Chief Investment Officer effective January 31, 2014. Mr. Kamer will continue to be employed by Douglas Emmett as a Senior Advisor. To read the full news, click here. Acacia Research (NASDAQ: ACTG) announced today that its Brandywine Communications Technologies LLC subsidiary has entered into a settlement and patent license agreement with Alcatel-Lucent USA (NYSE: ALU). To read the full news, click here.Posted-In: Benchmark US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets
Hot Sliver Companies For 2014: AcelRx Pharmaceuticals Inc.(ACRX)
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain in the United States. The company develops ARX-01, a Sufentanil NanoTab PCA system, which completed Phase II clinical trial for acute post-operative pain. The Sufentanil NanoTab PCA system consists of sufentanil, a high therapeutic index opioid; NanoTabs, a non-invasive sublingual dosage form; and a handheld PCA device that enables simple patient-controlled delivery of NanoTabs in the hospital setting and eliminates the risk of programming errors. Its products also include ARX-02, a Sufentanil NanoTab BTP Management System that completed Phase II clinical trial for the treatment of cancer breakthrough pain; and ARX-03, a Sufentanil/Triazolam NanoTab, which completed Phase II clinical trial to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a ph ysician?s office. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood, California.
Advisors' Opinion:- [By Roberto Pedone]
Another stock that insiders are jumping into here in a big way is AcelRx Pharmaceuticals (ACRX), which is involved in the development and commercialization of therapies for the treatment of acute and breakthrough pain. Insiders are buying this stock into major strength, since shares are up a whopping 177% so far in 2013.
AcelRx Pharmaceuticals has a market cap of $440 million and an enterprise value of $412 million. This stock trades at a premium valuation, with a price-to-sales of 145.48 and a price-to-book of 19.93. Its estimated growth rate for this year is 36.4%, and for next year it's pegged at 14.6%. This is a cash-rich company, since the total cash position on its balance sheet is $48.20 million and its total debt is $14.2 million.
A beneficial owner just bought 850,000 shares, or about $9.9 million worth of stock, at $11.65 per share.
From a technical perspective, ACRX is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock has been uptrending strong for the last six months, with shares exploding higher from its low of $4.31 to its recent high of $13.50 a share. During that move, this stock has been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of ACRX within range of triggering a major breakout trade.
If you're bullish on ACRX, then look for long-biased trades as long as this stock is trending some key near-term support levels at $11.46 to $11.43 a share or above its 50-day at $10.06, and then once it breaks out above some near-term overhead resistance levels at $12.57 to its all-time high at $13.50 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 637,219 shares. If that breakout hits soon, then ACRX will set up to enter new all-time-high territory above $13.50, which is bullish technical price action.
- [By Garrett Cook]
Healthcare shares fell 0.13 percent on Friday. Top losers in the sector included AcelRx Pharmaceuticals (NASDAQ: ACRX), down 18 percent, and Repligen (NASDAQ: RGEN), off 3.7 percent.
- [By Eric Volkman]
AcelRx (NASDAQ: ACRX ) has slapped a price tag on its recently announced common stock offering. The company's shares will be sold to the market in an underwritten public flotation at a cost of $11.65 apiece. The firm has also granted its underwriters a 30-day purchase option for up to an additional 570,000 shares.
No comments:
Post a Comment